Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NeuroVia logo — Dedicated to halting the progression of severe neurological...

NeuroVia

Dedicated to halting the progression of severe neurological disorders and improving patient outcomes.

Founded 2013 Series A Total: $14.00M Biopharma, Biotechnology +1

General Information

Company Name NeuroVia
Founded Year 2013
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with NeuroVia. To contact NeuroVia, visit neurovia-inc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About NeuroVia

NeuroVia is a biopharmaceutical and biotechnology startup dedicated to halting the progression of severe neurological disorders and improving patient outcomes. Founded in 2013, the company is committed to addressing unmet medical needs in neurological diseases, with the primary goal of arresting the onset of devastating neurological deficits associated with X-ALD. NeuroVia has received a significant $14.00M Series A investment on 20 July 2017 from notable investors including Novartis Venture Fund, Sanofi Ventures, Enso Ventures, and BioMed Ventures. This substantial funding reflects the confidence of key industry players in the potential of NeuroVia's innovative approach to effectively address the challenges posed by neurological disorders.

Taxonomy: neurological disorders, patient outcomes, neurological diseases, X-ALD, medical needs, neurological deficits, disease progression, treatment development, innovative therapies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $14.00M 4
Novartis Venture Fund Sanofi Ventures Enso Ventures
Novartis Venture Fund, Sanofi Ventures +2
20 Jul 2017

NeuroVia Alternatives & Competitors

View All Alternatives
NeuroVia vs
Pinteon Therapeutics
Pinteon Therapeutics

Pioneering therapies targeting Pin1 to normalize disease processes and enhance patient outcomes in c...

Series B
2-10 employees
Biotechnology, Health Care
NeuroVia vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
NeuroVia vs
Minerva Neurosciences
Minerva Neurosciences

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on...

Post-IPO Equity
9 employees
Biopharma, Biotechnology
View all alternatives

FAQ About NeuroVia

Dedicated to halting the progression of severe neurological disorders and improving patient outcomes.
NeuroVia was founded in 2013.
NeuroVia operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on neurological disorders, patient outcomes, neurological diseases and X-ALD.
NeuroVia has completed 1 funding round, raising a total of $14.00M. The latest funding stage is Series A.
Top alternatives and competitors to NeuroVia include Pinteon Therapeutics, Antharis Therapeutics, Inc., Minerva Neurosciences, Polaryx Therapeutics, RiMO Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeuroVia and Pinteon Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NeuroVia, https://bouncewatch.com/company/neurovia, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes